1
|
Volkova T, Simonova O, Perlovich G. Revisiting the Solubility-Permeability Relationship with Hydrophobic Drug Umifenovir in Pluronic Solutions: Impact of pH and Co-Solvent. Pharmaceutics 2023; 15:pharmaceutics15020422. [PMID: 36839743 PMCID: PMC9959244 DOI: 10.3390/pharmaceutics15020422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2023] [Revised: 01/24/2023] [Accepted: 01/25/2023] [Indexed: 01/31/2023] Open
Abstract
This study describes the influence of pluronic F-127 (F-127) and ethanol (EtOH) on the solubility of umifenovir (UMF) in buffer solutions of pH 2.0 and pH 7.4, and its permeability through cellulose membranes. A 44.4-fold greater UMF solubility in acidic medium as compared to an alkaline one was estimated at 310.15 K. The concentration of UMF in the saturated solution was enhanced by the interaction with F-127 micelles. The combined positive effect of EtOH and F-127 on the solubility was estimated. The aggregation number of F-127 micelles in the presence of 10% and 20% ethanol appeared to be reduced by 2.1-fold and 4.1-fold, respectively, as compared to buffer pH 7.4. The presence of ethanol in buffer pH 7.4 solution provided better solvent conditions but inhibited the formation of F-127 micelles. The impact of UMF on the aggregation number of F-127 was not pronounced and was expressed only by a slight increase of 1 and 3 units in 10% and 20% EtOH, respectively. According to the values of zeta potential, addition of EtOH reduced the stability of the system. The permeation of UMF in buffer pH 7.4 measured through the cellulose membrane MWCO 12-14 kDa was increased 1.4-fold by 10% EtOH. An increase in EtOH content to 20% reduced this effect to 1.2-fold. Decreasing effect of 1.5% F-127 on the permeability was inhibited by using 10% EtOH. The solution containing 1.5% F-127 and 10% EtOH was shown to be an advantageous system for UMF in view of the solubility-permeability balance. The authors suppose the findings of the study to be useful for the design of pharmaceutical formulations based on UMF antiviral drugs.
Collapse
|
2
|
Improving the Solubilization and Bioavailability of Arbidol Hydrochloride by the Preparation of Binary and Ternary β-Cyclodextrin Complexes with Poloxamer 188. Pharmaceuticals (Basel) 2021; 14:ph14050411. [PMID: 33926020 PMCID: PMC8145073 DOI: 10.3390/ph14050411] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Revised: 04/16/2021] [Accepted: 04/21/2021] [Indexed: 12/22/2022] Open
Abstract
In the current study, the effect of poloxamer 188 on the complexation efficiency and dissolution of arbidol hydrochloride (ADL), a broad-spectrum antiviral agent, with β-cyclodextrin (β-CD) was investigated. Phase solubility studies confirmed a stoichiometry of a 1:1 ratio for both ADL:β-CD and ADL/β-CD with a 1% poloxamer 188 system with an AL type of phase solubility curve. The stability constants (K1:1) calculated from the AL type diagram were 550 M-1 and 2134 M-1 for AD:β-CD and ADL/β-CD with 1% poloxamer 188, respectively. The binary ADL/β-CD and ternary ADL/β-CD with 1% poloxamer 188 complexes were prepared by kneading and a solvent evaporation method and were characterized by aqueous solubility, FTIR, PXRD, DSC and SEM in vitro studies. The solubility (13.1 fold) and release of ADL were markedly improved in kneaded ternary ADL/β-CD with 1% poloxamer 188 (KDB). The binding affinity of ADL and β-CD was confirmed by 1H NMR and 2D ROSEY studies. The ternary complex (KDB) was further subjected for in vivo pharmacokinetic studies in rats and a significant improvement in the bioavailability (2.17 fold) was observed in comparison with pure ADL. Therefore, it can be concluded that the solubilization and bioavailability of ADL can be remarkably increased by ADL/β-CD complexation in the presence of a third component, poloxamer 188.
Collapse
|
3
|
Li X, Wang X, Jiang Q, Chi F, Liu Q, Zhang T. The delivery of arbidol by salt engineering: synthesis, physicochemical properties and pharmacokinetics. Drug Dev Ind Pharm 2016; 43:151-159. [PMID: 27533023 DOI: 10.1080/03639045.2016.1225755] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The aim of the present study was to evaluate the feasibility of using the methanesulfonic salt of arbidol in order to improve its aqueous solubility and thus oral bioavailability. Arbidol mesylate (AM) was synthesized and then characterized using nuclear magnetic resonance spectroscopy (NMR), infrared spectroscopy (IR), powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC) and scanning electron microscopy (SEM), and its apparent solubility and octanol-water partition coefficient were also studied. The results of NMR, IR, PXRD, SEM and DSC tests confirmed the salt formation. The apparent solubility of AM in water was 32-fold higher than that of the commercial product. A superior pH-dependent profile and an improved dissolution rate of AM were obtained in a variety of solutions with different pH values. In addition, AM exhibited a relatively higher peak plasma concentration (1460 versus 1297 ng/mL) and an increased AUC0-t (2475 versus 1277 ng/mL × h) when comparing with the commercial product, indicating the improved bioavailability of the drug. This study suggests that AM may be able to improve the therapeutic efficacy of arbidol, which rendering it to be a promising candidate for further development.
Collapse
Affiliation(s)
- Xiaoting Li
- a Department of Pharmaceutical Analysis, School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , China
| | - Xu Wang
- a Department of Pharmaceutical Analysis, School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , China
| | - Qikun Jiang
- a Department of Pharmaceutical Analysis, School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , China
| | - Fangda Chi
- b Clinical Medical College of China Medical University , Shenyang , China
| | - Qian Liu
- a Department of Pharmaceutical Analysis, School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , China
| | - Tianhong Zhang
- a Department of Pharmaceutical Analysis, School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , China
| |
Collapse
|
4
|
Crystal Structures, Thermal Analysis, and Dissolution Behavior of New Solid Forms of the Antiviral Drug Arbidol with Dicarboxylic Acids. CRYSTALS 2015. [DOI: 10.3390/cryst5040650] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
5
|
Surov AO, Manin AN, Churakov AV, Perlovich GL. New Solid Forms of the Antiviral Drug Arbidol: Crystal Structures, Thermodynamic Stability, and Solubility. Mol Pharm 2015; 12:4154-65. [DOI: 10.1021/acs.molpharmaceut.5b00629] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Artem O. Surov
- G.A.
Krestov Institute of Solution Chemistry, Russian Academy of Sciences, 153045, Ivanovo, Russia
| | - Alex N. Manin
- G.A.
Krestov Institute of Solution Chemistry, Russian Academy of Sciences, 153045, Ivanovo, Russia
| | - Andrei V. Churakov
- Institute
of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii Prospekt 31, 119991 Moscow, Russia
| | - German L. Perlovich
- G.A.
Krestov Institute of Solution Chemistry, Russian Academy of Sciences, 153045, Ivanovo, Russia
| |
Collapse
|
6
|
Oestereich L, Rieger T, Neumann M, Bernreuther C, Lehmann M, Krasemann S, Wurr S, Emmerich P, de Lamballerie X, Ölschläger S, Günther S. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis 2014; 8:e2804. [PMID: 24786461 PMCID: PMC4006714 DOI: 10.1371/journal.pntd.0002804] [Citation(s) in RCA: 121] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2013] [Accepted: 03/09/2014] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Mice lacking the type I interferon receptor (IFNAR-/- mice) reproduce relevant aspects of Crimean-Congo hemorrhagic fever (CCHF) in humans, including liver damage. We aimed at characterizing the liver pathology in CCHF virus-infected IFNAR-/- mice by immunohistochemistry and employed the model to evaluate the antiviral efficacy of ribavirin, arbidol, and T-705 against CCHF virus. METHODOLOGY/PRINCIPAL FINDINGS CCHF virus-infected IFNAR-/- mice died 2-6 days post infection with elevated aminotransferase levels and high virus titers in blood and organs. Main pathological alteration was acute hepatitis with extensive bridging necrosis, reactive hepatocyte proliferation, and mild to moderate inflammatory response with monocyte/macrophage activation. Virus-infected and apoptotic hepatocytes clustered in the necrotic areas. Ribavirin, arbidol, and T-705 suppressed virus replication in vitro by ≥3 log units (IC50 0.6-2.8 µg/ml; IC90 1.2-4.7 µg/ml). Ribavirin [100 mg/(kg×d)] did not increase the survival rate of IFNAR-/- mice, but prolonged the time to death (p<0.001) and reduced the aminotransferase levels and the virus titers. Arbidol [150 mg/(kg×d)] had no efficacy in vivo. Animals treated with T-705 at 1 h [15, 30, and 300 mg/(kg×d)] or up to 2 days [300 mg/(kg×d)] post infection survived, showed no signs of disease, and had no virus in blood and organs. Co-administration of ribavirin and T-705 yielded beneficial rather than adverse effects. CONCLUSIONS/SIGNIFICANCE Activated hepatic macrophages and monocyte-derived cells may play a role in the proinflammatory cytokine response in CCHF. Clustering of infected hepatocytes in necrotic areas without marked inflammation suggests viral cytopathic effects. T-705 is highly potent against CCHF virus in vitro and in vivo. Its in vivo efficacy exceeds that of the current standard drug for treatment of CCHF, ribavirin.
Collapse
Affiliation(s)
- Lisa Oestereich
- Department of Virology, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany
- German Centre for Infection Research (DZIF), Hamburg, Germany
| | - Toni Rieger
- Department of Virology, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany
- German Centre for Infection Research (DZIF), Hamburg, Germany
| | - Melanie Neumann
- Mouse Pathology Core Facility, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Christian Bernreuther
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Maria Lehmann
- Department of Virology, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany
- German Centre for Infection Research (DZIF), Hamburg, Germany
| | - Susanne Krasemann
- Mouse Pathology Core Facility, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Stephanie Wurr
- Department of Virology, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany
- German Centre for Infection Research (DZIF), Hamburg, Germany
| | - Petra Emmerich
- Department of Virology, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany
- German Centre for Infection Research (DZIF), Hamburg, Germany
| | - Xavier de Lamballerie
- Aix Marseille Université, IRD French Institute of Research for Development, EHESP French School of Public Health, UMR_D 190 “Emergence des Pathologies Virales”, Marseille, France
| | - Stephan Ölschläger
- Department of Virology, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany
| | - Stephan Günther
- Department of Virology, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany
- German Centre for Infection Research (DZIF), Hamburg, Germany
| |
Collapse
|
7
|
Blaising J, Polyak SJ, Pécheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 2014; 107:84-94. [PMID: 24769245 PMCID: PMC7113885 DOI: 10.1016/j.antiviral.2014.04.006] [Citation(s) in RCA: 302] [Impact Index Per Article: 30.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2013] [Revised: 03/04/2014] [Accepted: 04/14/2014] [Indexed: 12/12/2022]
Abstract
Arbidol (ARB) is licensed in Russia and China for the treatment of influenza and other viral infections. ARB inhibits a large panel of viral pathogens, enveloped or not. ARB displays a dual binding activity to lipid membranes and to viral or cellular proteins. It blocks viral endocytosis and replication in membranous intracellular compartments.
Arbidol (ARB) is a Russian-made small indole-derivative molecule, licensed in Russia and China for prophylaxis and treatment of influenza and other respiratory viral infections. It also demonstrates inhibitory activity against other viruses, enveloped or not, responsible for emerging or globally prevalent infectious diseases such as hepatitis B and C, gastroenteritis, hemorrhagic fevers or encephalitis. In this review, we will explore the possibility and pertinence of ARB as a broad-spectrum antiviral, after a careful examination of its physico-chemical properties, pharmacokinetics, toxicity, and molecular mechanisms of action. Recent studies suggest that ARB’s dual interactions with membranes and aromatic amino acids in proteins may be central to its broad-spectrum antiviral activity. This could impact on the virus itself, and/or on cellular functions or critical steps in virus-cell interactions, thereby positioning ARB as both a direct-acting antiviral (DAA) and a host-targeting agent (HTA). In the context of recent studies in animals and humans, we will discuss the prospective clinical use of ARB in various viral infections.
Collapse
Affiliation(s)
- Julie Blaising
- CRCL, Inserm U1052, CNRS 5286, University of Lyon, Lyon, France
| | - Stephen J Polyak
- Dept of Laboratory Medicine, University of Washington, Seattle, WA, USA; Dept of Global Health, University of Washington, Seattle, WA, USA
| | | |
Collapse
|
8
|
Rudovica V, Viksna A, Actins A. Application of LA-ICP-MS as a rapid tool for analysis of elemental impurities in active pharmaceutical ingredients. J Pharm Biomed Anal 2014; 91:119-22. [DOI: 10.1016/j.jpba.2013.12.025] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Revised: 12/17/2013] [Accepted: 12/21/2013] [Indexed: 11/25/2022]
|
9
|
Chernyshev VV, Davlyatshin DI, Shpanchenko RV, Nosyrev PV. Structural characterization of arbidol®. ACTA ACUST UNITED AC 2011. [DOI: 10.1524/zkri.2011.1399] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Abstract
Crystal structures of two compounds – 1-methyl-2-phenylthiomethyl-3-carbethoxy-4-dimetylaminomethyl-5-hydroxy-6-bromoindole (1) and its hydrochloride monohydrate (2), known also as antiviral drug arbidol®, were determined from single-crystal and powder diffraction data, respectively. In 1, the hydroxyl and dimethyläamino groups are involved in a strong intramolecular O—H…N hydrogen bond [O…N 2.550(4) Å]. In 2, the protonation site is dimethylamino group but not the carbon bearing the ester group.
Collapse
Affiliation(s)
| | | | | | - Pavel V. Nosyrev
- Moscow State University, Department of Chemistry, Moscow, Russische Föderation
| |
Collapse
|
10
|
|